Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT), Lancet. 2 avr, vol.387, pp.1415-1441, 2016. ,
Biomarqueurs France : résultats à long terme du profilage moléculaire en routine des cancers bronchiques non à petites cellules, Abstr Mal Respir. janv, vol.36, pp.38-47, 2019. ,
Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients, Indian J Cancer. juin, vol.50, issue.2, pp.107-118, 2013. ,
Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER), J Thorac Oncol. févr, vol.9, issue.2, pp.154-62, 2014. ,
Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, Chest. mai, vol.143, issue.5, pp.142-165, 2013. ,
The 2015 World Health Organization Classification of Lung Tumors, J Thorac Oncol. sept, vol.10, issue.9, pp.1243-60, 2015. ,
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. févr, vol.6, issue.2, pp.244-85, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00561753
, Délais de prise en charge des quatre cancers les plus fréquents dans plusieurs régions de France en 2011 et 2012 : sein, poumon, côlon, prostate
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer, J Thorac Oncol. janv, vol.11, issue.1, pp.39-51, 2016. ,
The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol, vol.9, issue.11, pp.1618-1642, 2014. ,
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer, vol.10, issue.11, pp.1515-1537, 2015. ,
Histological typing of lung and pleural tumours, 1999. ,
et le comité de rédaction des référentiels Auvergne Rhône-Alpes en oncologie thoracique. Référentiel sur le cancer bronchique non à petites-cellules : actualisation 2019. ARISTOT, 2019. ,
Nouvelle classification des cancers pulmonaires : application aux prélèvements biopsiques de petite taille, Ann Pathol, vol.30, issue.5, pp.60-63, 2010. ,
Molecular footprints of human lung cancer progression, Cancer Sci, vol.95, issue.3, pp.197-204, 2004. ,
Hallmarks of Cancer: The Next Generation. Cell. 4 mars, vol.144, pp.646-74, 2011. ,
Mutational heterogeneity in cancer and the search for new cancer genes, Nature. 11 juill, vol.499, issue.7457, pp.214-222, 2013. ,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med. 20 mai, vol.350, issue.21, pp.2129-2168, 2004. ,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med. 20 juin, vol.368, issue.25, pp.2385-94, 2013. ,
Genotyping and Genomic Profiling of Non-Small-Cell Lung Cancer: Implications for Current and Future Therapies, J Clin Oncol. 10 mars, vol.31, issue.8, pp.1039-1088, 2013. ,
, Synthèse de l'activité des plateformes hospitalières de génétique moléculaire des cancers en 2012, en vue d'optimiser leur évolution, janv, 2014.
American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest. mai, vol.143, issue.5, pp.30-39, 2013. ,
DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci U S A. déc, vol.74, issue.12, pp.5463-5470, 1977. ,
, Plateformes hospitalières de génétique moléculaire des cancers
Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study, J Thorac Oncol. 1 févr, vol.7, issue.2, pp.348-54, 2012. ,
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, J Clin Oncol. 21 sept, 2016. ,
The deaf and the dumb: the biology of ErbB-2 and ErbB-3, Exp Cell Res. 10 mars, vol.284, issue.1, pp.54-65, 2003. ,
Ligand-Induced, Receptor-Mediated Dimerization and Activation of EGF Receptor, Cell. 20 sept, vol.110, issue.6, pp.669-72, 2002. ,
PI(3)K and mTOR signalling controls tumour cell growth, Nature. 25 mai, vol.441, issue.7092, pp.424-454, 2006. ,
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions, J Clin Oncol. avr, vol.23, issue.11, pp.2556-68, 2005. ,
, Tumeurs intra-thoraciques: mutations oncogéniques et problématiques cliniques: prédisposition génétique au cancer broncho-pulmonaire chez le patient non-fumeur: hétérogénéité inter-et intra-tumorale des cancers broncho-pulmonaires: étude génomique intégrative des tumeurs épithéliales du thymus
, Français. NNT : 2011LYO10142. tel-00926538, p.97, 2011.
Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions, J Clin Oncol, vol.23, issue.11, pp.2556-68, 2005. ,
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced nonsmall-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 15 mars, vol.22, issue.6, pp.1103-1112, 2004. ,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science. 4 juin, vol.304, issue.5676, pp.1497-500, 2004. ,
EGF receptor gene mutations are common in lung cancers from « never smokers » and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci, vol.101, issue.36, pp.13306-13317, 2004. ,
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, vol.118, issue.2, pp.257-62, 2006. ,
Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database, J Thorac Oncol. 1 août, vol.3, issue.8, pp.832-841, 2008. ,
Genetic profiling and epidermal growth factor receptordirected therapy in nonsmall cell lung cancer, Eur Respir J. 1 janv, vol.37, issue.1, pp.183-93, 2011. ,
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network, Ann Oncol. janv, vol.25, issue.1, pp.126-157, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02181347
Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response, Clin Cancer Res. 1 août, vol.14, issue.15, pp.4877-82, 2008. ,
New driver mutations in non-small-cell lung cancer, Lancet Oncol. 1 févr, vol.12, issue.2, pp.175-80, 2011. ,
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer, Cancer Sci. 1 déc, vol.98, issue.12, pp.1817-1841, 2007. ,
Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations, Curr Med Chem. 31 mars, vol.18, issue.11, pp.1613-1641, 2011. ,
Epidermal growth factor receptor mutations in lung cancer, Nat Rev Cancer. mars, vol.7, issue.3, pp.169-81, 2007. ,
EGFR T790M resistance mutation in non small-cell lung carcinoma, Clin Chim Acta. avr, vol.444, pp.81-86, 2015. ,
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report, Clin Cancer Res Off J Am Assoc Cancer Res. 15 janv, vol.16, issue.2, pp.755-63, 2010. ,
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR, Nat Genet. déc, vol.37, issue.12, pp.1315-1321, 2005. ,
Brief report: Screening for germline EGFR T790M mutations through lung cancer genotyping, J Thorac Oncol. juin, vol.7, issue.6, pp.1049-52, 2012. ,
Presence of Epidermal Growth Factor Receptor Gene T790M Mutation as a Minor Clone in Non-Small Cell Lung Cancer, Cancer Res. 15 août, vol.66, issue.16, pp.7854-7862, 2006. ,
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer, J Thorac Oncol. 1 avr, vol.12, issue.4, pp.612-635, 2017. ,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med. 3 sept, vol.361, issue.10, pp.947-57, 2009. ,
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer, N Engl J Med. 3 sept, vol.361, issue.10, pp.958-67, 2009. ,
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation, Clin Cancer Res. 15 mars, vol.17, issue.6, pp.1616-1638, 2011. ,
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay, Clin Cancer Res. 1 mars, vol.17, issue.5, pp.1169-80, 2011. ,
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer, N Engl J Med. 6 déc, vol.376, issue.7, pp.629-669, 2016. ,
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers, Clin Cancer Res. 15 avr, vol.19, issue.8, pp.2240-2247, 2013. ,
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 4 mars, vol.263, pp.1281-1285, 1994. ,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature. août, vol.448, issue.7153, pp.561-567, 2007. ,
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors, Clin Epidemiol, vol.6, pp.423-455, 2014. ,
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer, Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill, vol.14, issue.13, pp.4275-83, 2008. ,
EML4-ALK: honing in on a new target in non-small-cell lung cancer, J Clin Oncol Off J Am Soc Clin Oncol. 10 sept, vol.27, issue.26, pp.4232-4237, 2009. ,
EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues, Am J Pathol. 1 févr, vol.174, issue.2, pp.661-70, 2009. ,
EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset, Mod Pathol. avr, vol.22, issue.4, pp.508-523, 2009. ,
The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS, Cancer. 15 avr, vol.115, issue.8, pp.1723-1756, 2009. ,
Targeting brain metastases in ALKrearranged non-small-cell lung cancer, Lancet Oncol, vol.16, issue.13, pp.510-521, 2015. ,
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer, Clin Cancer Res. 1 mars, vol.18, issue.5, pp.1472-82, 2012. ,
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non-Small-Cell Lung Cancer, J Thorac Oncol, vol.7, issue.11, pp.1625-1655, 2012. ,
ROS1 and ALK fusions in lung cancer, Nat Med. mars, vol.18, issue.3, pp.378-81, 2012. ,
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers, J Clin Oncol. 3 janv, vol.30, issue.8, pp.863-70, 2012. ,
Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis, Transl Lung Cancer Res. juin, vol.4, issue.3, pp.300-309, 2015. ,
Crizotinib in ROS1-Rearranged Non-Small-Cell Lung Cancer, N Engl J Med, vol.371, issue.21, pp.1963-71, 2014. ,
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort, J Clin Oncol. 9 févr, vol.33, issue.9, pp.992-1001, 2015. ,
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial, J Clin Oncol. 20 mai, vol.33, pp.8065-8065, 2015. ,
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer, JCO Precis Oncol, 2017. ,
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer, Clin Cancer Res. 15 juill, vol.24, issue.14, pp.3334-3381, 2018. ,
Raf Kinases: Function, Regulation and Role in Human Cancer, Biochim Biophys Acta. août, vol.1773, issue.8, pp.1196-212, 2007. ,
Mutations of the BRAF gene in human cancer, Nature. juin, vol.417, issue.6892, p.949, 2002. ,
Missense mutations of the BRAF gene in human lung adenocarcinoma, Cancer Res. 1 déc, vol.62, issue.23, pp.7001-7004, 2002. ,
Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer, J Surg Res, vol.133, issue.2, pp.203-209 ,
Somatic mutations affect key pathways in lung adenocarcinoma, Nature, vol.455, issue.7216, pp.1069-75, 2008. ,
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib, PLoS Med. janv, vol.2, issue.1, p.17, 2005. ,
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors, J Clin Oncol. 20 mai, vol.37, pp.3003-3003, 2019. ,
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene, Science. 6 déc, vol.230, issue.4730, pp.1132-1141, 1985. ,
Lung cancer: intragenic ERBB2 kinase mutations in tumours, Nature, vol.431, issue.7008, pp.525-531, 2004. ,
Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers, Lung Cancer, vol.74, issue.1, pp.139-183, 2011. ,
clinicopathologic associations and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas, Clin Cancer Res Off J Am Assoc Cancer Res. 15 sept, vol.18, issue.18, pp.4910-4918, 2012. ,
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas, Cancer Res. 1 mars, vol.65, issue.5, pp.1642-1648, 2005. ,
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives, J Clin Oncol. 1 juin, vol.31, issue.16, pp.1997-2003, 2013. ,
Phase II trial of trastuzumab in combination with pertuzumab in pretreated patients with non-small cell lung cancer (NSCLC) harboring a Her2 mutation and receiving docetaxel R2D2 trial (Her2-positive lung cancer treated with Dedicated Drug). IFCT-1703 R2D2 ,
The role of the c-Met pathway in lung cancer and the potential for targeted therapy, Ther Adv Med Oncol. juill, vol.3, issue.4, pp.171-84, 2011. ,
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers, JNCI J Natl Cancer Inst. 1 mai, vol.109, issue.5, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02413937
MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC, Virchows Arch. 1 juill, vol.471, issue.1, pp.49-55, 2017. ,
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors, Cancer Discov. 1 août, vol.5, issue.8, pp.850-859, 2015. ,
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta TM Panel: exploring therapeutic targets, Ann Oncol. 1 août, vol.26, issue.8, pp.1748-53, 2015. ,
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung, Oncotarget. 21 mars, vol.8, issue.26, pp.42428-42465, 2017. ,
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis, Clin Cancer Res. 15 juin, vol.22, issue.12, pp.3048-56, 2016. ,
Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase, EMBO J. 2 févr, vol.17, issue.3, pp.743-53, 1998. ,
High Frequency of Mutations of the PIK3CA Gene in Human Cancers | Science, Science. avr, vol.304, issue.5670, p.554, 2004. ,
PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer, vol.54, pp.209-224, 2006. ,
Inherited lung cancer syndromes targeting never smokers, Transl Lung Cancer Res. 21 juin, vol.7, issue.4, pp.498-504, 2018. ,
PIK3CA mutation and amplification in human lung cancer, Pathol Int, vol.57, issue.10, pp.664-71, 2007. ,
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma -rationale for comprehensive mutation profiling, Mol Cancer Ther. févr, vol.11, issue.2, pp.485-91, 2012. ,
PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer, vol.58, pp.159-60, 2007. ,
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification, J Pathol, vol.214, issue.3, pp.347-56, 2008. ,
Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations: Results from the IFCT Study Biomarkers France, J Thorac Oncol. juin, vol.12, issue.6, pp.963-73, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01699240
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts, Br J Cancer. mai, vol.110, issue.11, pp.2812-2832, 2014. ,
Tumor Evasion from T Cell Surveillance, BioMed Res Int, p.918471, 2011. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer. avr, vol.12, issue.4, pp.252-64, 2012. ,
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway, Trends Mol Med. 1 janv, vol.21, issue.1, pp.24-33, 2015. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.375, issue.19, pp.1823-1856, 2016. ,
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, vol.373, issue.17, pp.1627-1666, 2015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet, vol.9, pp.1540-50, 2016. ,
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC), J Thorac Oncol. 1 juin, vol.14, issue.6, pp.1095-101, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02104417
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry, Ann Oncol. 1 août, vol.30, issue.8, pp.1321-1329, 2019. ,
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer, N Engl J Med, vol.377, issue.20, pp.1919-1948, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01753457
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med. 24 juin, vol.362, issue.25, pp.2380-2388, 2010. ,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial, Lancet Oncol. févr, vol.11, issue.2, pp.121-129, 2010. ,
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, J Clin Oncol. 20 avr, vol.33, issue.17, pp.1958-65, 2015. ,
Osimertinib in Untreated EGFR -Mutated Advanced Non-Small-Cell Lung Cancer, N Engl J Med. 11 janv, vol.378, issue.2, pp.113-138, 2018. ,
First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med. 4 déc, vol.371, issue.23, pp.2167-77, 2014. ,
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. 26 mars, vol.370, pp.1189-97, 2014. ,
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet. 4 mars, vol.389, pp.917-946, 2017. ,
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer, N Engl J Med, vol.31, issue.9, pp.829-867, 2017. ,
Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC), J Clin Oncol. 20 mai, vol.37, pp.9092-9092, 2019. ,
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial, J Clin Oncol Off J Am Soc Clin Oncol. 1 août, vol.35, issue.22, pp.2490-2498, 2017. ,
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial, Lancet Oncol, vol.18, issue.12, pp.1590-1599, 2017. ,
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial, Lancet Oncol, vol.17, issue.5, pp.642-50, 2016. ,
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic nonsmall cell lung cancer: an open-label, multicentre phase 2 trial, Lancet Oncol. juill, vol.17, issue.7, pp.984-93, 2016. ,
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic nonsmall-cell lung cancer: an open-label, phase 2 trial, Lancet Oncol, vol.18, issue.10, pp.1307-1323, 2017. ,
Commission de transparence, 2018. ,
Capmatinib (INC280) in MET?ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study, J Clin Oncol. 20 mai, vol.37, pp.9004-9004, 2019. ,
Effect of delays on prognosis in patients with non-small cell lung cancer, Thorax. 1 janv, vol.59, issue.1, pp.45-54, 2004. ,
Timeliness of care and prognosis in patients with lung cancer, Ir J Med Sci, vol.183, issue.3, pp.383-90, 1971. ,
Timeliness of access to lung cancer diagnosis and treatment: A scoping literature review. Lung Cancer, vol.112, pp.156-64, 2017. ,
Timeliness of care in patients with lung cancer: a systematic review, Thorax. 1 sept, vol.64, issue.9, pp.749-56, 2009. ,
Treatment Delays in Non-small Cell Lung Cancer and Their Prognostic Implications, J Thorac Oncol. 1 juill, vol.6, issue.7, pp.1254-1263, 2011. ,
Survival After Community Diagnosis of Early-stage Non-small Cell Lung Cancer, Am J Med. 1 mai, vol.127, issue.5, pp.443-452, 2014. ,
Rapid Disease Progression With Delay in Treatment of Non-Small-Cell Lung Cancer, Int J Radiat Oncol. 1 févr, vol.79, issue.2, pp.466-72, 2011. ,
Diagnostic delay causes more psychological distress in female than in male cancer patients, Anticancer Res. avr, vol.16, issue.2, pp.995-1004, 1996. ,
, Étude sur les délais de prise en charge des cancers du sein et du poumon
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, vol.144, issue.8, pp.1941-1953, 2018. ,
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries, Lancet. 17 mars, vol.391, pp.1023-75, 2018. ,
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2), Lancet. mars, vol.385, issue.9972, pp.977-1010, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01912088
International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women, Lung Cancer. 1 avr, vol.84, issue.1, pp.13-22, 2014. ,
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap), Ann Oncol. sept, vol.24, issue.9, pp.2371-2377, 2013. ,
Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity, PLoS One, vol.8, issue.10, p.76164, 2013. ,
Detection of EGFR gene mutations in non-small cell lung cancer: Lessons from a single-institution routine analysis of 1,403 tumor samples, Int J Oncol, vol.07, issue.4, pp.1045-51, 2013. ,
EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery, J Thorac Oncol. 1 mai, vol.6, issue.5, pp.947-50, 2011. ,
Evaluation of 2-Year Experience With EGFR Mutation Analysis of Small Diagnostic Samples, Diagn Mol Pathol. 1 juin, vol.22, issue.2, pp.70-75, 2013. ,
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII), Am J Cancer Res, vol.5, issue.9, pp.2892-2911, 2015. ,
Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Résultats préliminaires. Rapport. Saint-Maurice (Fra) : Santé publique France, 2019. ,
Les Cancers à La Réunion ,
Le cancer broncho-pulmonaire dans le département de La Réunion: caractéristiques cliniques et démographiques ,
Estimation nationale de l'incidence et de la mortalité par cancer en France entre 1980 et 2012. Etude à partir des registres des cancers du réseau Francim. Partie 1. Tumeurs solides ,
Évolution en 10ans du cancer bronchique non à petites cellules en fonction du sexe. Résultats de l'étude KBP-2010-CPHG du Collège des pneumologues des hôpitaux généraux, Rev Mal Respir, vol.31, issue.9, pp.805-821, 2014. ,
Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis, Lung Cancer. 1 mars, vol.31, issue.2, pp.139-187, 2001. ,
Do changes in cigarette design influence the rise in adenocarcinoma of the lung?, Cancer Causes Control. 1 janv, vol.22, issue.1, pp.13-22, 2011. ,
Risk factors for lung cancer worldwide, Eur Respir J, vol.48, issue.3, pp.889-902, 2016. ,
Smoking and Carcinoma of the Lung, Br Med J. 30 sept, vol.2, issue.4682, pp.739-787, 1950. ,
, Les usages de drogues dans les DOM en 2014 chez les adolescents et les adultes -Tendances 111 -juillet 2016 2 -OFDT
,
Baromètre santé DOM 2014. Tabagisme et usage d'e-cigarette, vol.14, 2014. ,
International Agency for Research on Cancer. Agents classified by the IARC monographs. volumes 1-122, Premiers résultats du baromètre santé, vol.168, 2017. ,
Residential radon and lung cancer-detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14 208 persons without lung cancer from 13 epidemiologic studies in Europe, Scand J Work Environ Health, vol.32, issue.1, pp.1-84, 2006. ,
Incidence of Lung Adenocarcinoma Biomarker in a Caribbean and African Caribbean Population, J Thorac Oncol. 1 mai, vol.11, issue.5, pp.769-73, 2016. ,
Lung Cancer and Indoor Pollution from Heating and Cooking with Solid Fuels, Am J Epidemiol. 15 août, vol.162, issue.4, pp.326-359, 2005. ,
Dose-Response Relationship between Cooking Fumes Exposures and Lung Cancer among Chinese Nonsmoking Women, Cancer Res. 1 mai, vol.66, issue.9, pp.4961-4968, 2006. ,
Cannabis use and risk of lung cancer: a case-control study, Eur Respir J. 1 févr, vol.31, issue.2, pp.280-286, 2008. ,
An epidemiologic review of marijuana and cancer: an update, Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. janv, vol.24, issue.1, pp.15-31, 2015. ,
Lung cancer in never smokers -a different disease, Nat Rev Cancer, vol.7, issue.10, pp.778-90, 2007. ,
Lung Cancer in Never Smokers: A Review, J Clin Oncol. 10 févr, vol.25, issue.5, pp.561-70, 2007. ,
Lung cancer in never smokers -A review, Eur J Cancer. 1 juin, vol.48, issue.9, pp.1299-311, 2012. ,
Rising lung cancer mortality among nonsmokers, J Natl Cancer Inst. avr, vol.62, issue.4, pp.755-60, 1979. ,
Incidence of lung cancer in a large cohort of non-smoking men from Sweden, Int J Cancer, vol.94, issue.4, pp.591-594, 2001. ,
Indirect estimates of lung cancer death rates in Italy not attributable to active smoking. Epidemiol Camb Mass, vol.4, pp.502-512, 1993. ,
Lung Cancer Incidence in Never Smokers, J Clin Oncol. 10 févr, vol.25, issue.5, pp.472-480, 2007. ,
Global Cancer Statisticsy, CA Cancer J Clin, vol.385, issue.9972, pp.977-1010, 2014. ,
Estimates of worldwide burden of cancer in 2008: GLOBOCAN, Int J Cancer. 15 déc, vol.127, issue.12, pp.2893-917, 2008. ,
Lung Cancer Occurrence in Never-Smokers: An Analysis of 13 Cohorts and 22 Cancer Registry Studies, PLOS Med. 9 sept, vol.5, issue.9, p.185, 2008. ,
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity, J Clin Oncol. 20 mai, vol.24, issue.15, pp.2245-51, 2006. ,
Never-smoking nonsmall cell lung cancer as a separate entity, Cancer, vol.113, issue.5, pp.1012-1020, 2008. ,
Lung cancer in never smokers: a new hot area of research, Lancet Oncol. 1 avr, vol.11, issue.4, pp.304-309, 2010. ,
Nonsmall cell lung cancer in never smokers, Curr Opin Oncol. 1 mars, vol.21, issue.2, pp.99-104, 2009. ,
Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases, Ann Oncol. 1 juill, vol.13, issue.7, pp.1087-93, 2002. ,
A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival, Clin Lung Cancer. 1 sept, vol.19, issue.5, pp.539-50, 2018. ,
Worldwide Epidemiological Patterns of Lung Cancer in Nonsmokers, Int J Epidemiol. 1 janv, vol.19, issue.Supplement_1, pp.14-23, 1990. ,
Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer, Cancer. 1 févr, vol.116, issue.3, pp.670-675, 2010. ,
Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung, Chest. 1 août, vol.126, issue.2, pp.347-51, 2004. ,
Secondhand smoke exposure in adulthood and risk of lung cancer among never smokers: a pooled analysis of two large studies, Int J Cancer. mars, vol.109, issue.1, pp.125-156, 2004. ,
Environmental Tobacco Smoke and Lung Cancer in Nonsmoking Women: A Multicenter Study, Jama. 8 juin, vol.271, issue.22, pp.1752-1761, 1994. ,
Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies, BMJ. 29 janv, vol.330, issue.7485, p.223, 2005. ,
Residential Radon and Risk of Lung Cancer: A Combined Analysis of 7 North American Case-Control Studies, Epidemiology. 1 mars, vol.16, issue.2, pp.137-182, 2005. ,
,
, Rev Mal Respir, vol.25, issue.8, pp.3-18, 2008.
Long-term ambient fine particulate matter air pollution and lung cancer in a large cohort of never-smokers, Am J Respir Crit Care Med. 15 déc, vol.184, issue.12, pp.1374-81, 2011. ,
The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women, Cancer Res. 1 avr, vol.61, issue.7, pp.2799-803, 2001. ,
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations, J Clin Oncol. 11 avr, vol.29, issue.15, pp.2046-51, 2011. ,
Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History, Cancer Res. 15 juin, vol.67, issue.12, pp.5667-72, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00173094
Case-control study of familial lung cancer risks in UK women, Int J Cancer, vol.116, issue.3, pp.445-50, 2005. ,
Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses, Cancer Causes Control. 1 juill, vol.21, issue.7, pp.1091-104, 2010. ,
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25, Nature. avr, vol.452, issue.7187, pp.633-640, 2008. ,
URL : https://hal.archives-ouvertes.fr/cea-00944415
Tableaux de l'économie française ,
Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas, J Clin Oncol. 11 avr, vol.29, issue.15, pp.2066-70, 2011. ,
Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung, OncoTargets Ther. 5 janv, vol.8, pp.117-140, 2015. ,
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer, Lung Cancer Amst Neth, vol.114, pp.96-102, 2017. ,
EGFR exon 20 insertion mutations in non-smallcell lung cancer: preclinical data and clinical implications, Lancet Oncol. janv, vol.13, issue.1, pp.23-31, 2012. ,
Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions, J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. févr, vol.8, issue.2, pp.179-84, 2013. ,
Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer, Clin Cancer Res. 1 juin, vol.17, issue.11, pp.3812-3833, 2011. ,
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma, Eur Respir J. 1 févr, vol.39, issue.2, pp.366-72, 2012. ,
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression, Classification TNM, 8ème édition : T (9,13) Tableau 9 : Classification TNM, 8ème édition : N (9,13) Tableau 10 : Classification TNM, 8ème édition : M, vol.9, p.188, 2013. ,